Phase III, randomized, double-blind, active-controlled, parallel-group study, comparing the efficacy, safety and tolerability of the fixed dose combination of FF/UMEC/VI with the fixed dose dual combination of FF/VI, administered once-daily via a dry powder inhaler in subjects with inadequately controlled ASTHMA.
This study is comparing a triple fixed-dose combination product compared to a dual fixed-dose combination product in patients with asthma not adequately controlled. This study is for adults age 18 and above. There is compensation provided for time and travel. The study duration is a minimum of 24 weeks and a maximum of 52 weeks depending upon your time of enrollment. For more information, please contact our office at 636-946-1650
Condition | Asthma |
---|---|
Clinical Study Identifier | TX147792 |
Sponsor | GlaxoSmithKline |
Last Modified on | 23 November 2020 |
,
You have contacted , on
Your message has been sent to the study team at ,
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreEvery year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer
Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!
No annotations made yet
Congrats! You have your own personal workspace now.